 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical conditions, will be hosting a call today with two therapeutic area experts to discuss the first known reported finding of retinal tissue regeneration in a patient receiving a retinal pigment epithelium RPE cell transplant for the treatment of dry age-related macular degeneration AMD. Lineage management will be joined by therapeutic area experts Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, Barcelona Macula Foundation, and Michael S. Ip, M.D., Chief of Vitreoretinal Surgery Service, Doheny Eye Centers, UCLA, to discuss this new data from the Phase 12a study of OpRegen, the companys lead product candidate. Interested parties can access the live webcast on the Events and Presentations section of Lineages website today at 4:30pm Eastern Time 1:30pm Pacific Time. 